Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation
Author:
Publisher
Elsevier BV
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference35 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;Ca - Cancer J. Clin.,2021
2. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities;Yarden;Eur. J. Cancer,2001
3. Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer;Liu;Oncotarget,2017
4. A comprehensive pathway map of epidermal growth factor receptor signaling;Oda;Mol. Syst. Biol.,2005
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors;Future Medicinal Chemistry;2024-08-29
2. Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC);Bioorganic & Medicinal Chemistry;2024-07
3. EGFR degraders in non‐small‐cell lung cancer: Breakthrough and unresolved issue;Chemical Biology & Drug Design;2024-04
4. Annual review of PROTAC degraders as anticancer agents in 2022;European Journal of Medicinal Chemistry;2024-03
5. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation;European Journal of Medicinal Chemistry;2024-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3